Last updated: February 27, 2026
What Is the Drug and Its Market Position?
NDC 24385-0602 corresponds to Evolocumab (sold as Repatha), a monoclonal antibody developed for hyperlipidemia management. It is part of PCSK9 inhibitors, approved by the FDA in 2015. Evolocumab treats conditions requiring LDL cholesterol reduction, primarily familial hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD).
Evolocumab's market share is significant, given its unique mechanism and efficacy. As of 2022, it holds an estimated market penetration rate of 70-80% in the PSCK9 inhibitors segment, with competitors including Alirocumab (Praluent) from Regeneron.
Global and U.S. Market Size
Market Size (2023)
| Region |
Market Size (USD Billion) |
Notes |
| U.S. |
$4.2 |
Dominates due to high prevalence of hyperlipidemia |
| Europe |
$2.1 |
Significant adoption, high pricing pressure |
| Asia-Pacific |
$0.8 |
Growing, but limited by access and affordability |
Total global market for PCSK9 inhibitors in 2023: approximately $7-8 billion.
Key Market Drivers
- Increase in hypercholesterolemia prevalence.
- Growing awareness of cardiovascular risk management.
- Favorable reimbursement policies in the U.S.
- Expanded indications and label updates (e.g., treatment of HoFH).
Competitive Landscape
| Drug |
Company |
Approval Year |
Indications |
Market Share (2023) |
| Evolocumab (Repatha) |
Amgen |
2015 |
FH, ASCVD |
~75% |
| Alirocumab (Praluent) |
Regeneron |
2015 |
FH, ASCVD |
~20% |
| Inclisiran |
Novartis |
2020 |
LDL reduction, chronic use |
5% |
Price Trends and Projections
Current Pricing (2023)
| Region |
Wholesale Acquisition Cost (WAC) per year |
Notes |
| U.S. |
~$14,100 |
List price; discounts and rebates reduce net price by ~20-30% |
| Europe |
€5,600-€8,000 |
Varies by country, reimbursement negotiations vary |
| Asia-Pacific |
$12,000-$15,000 |
Limited distribution, pricing sensitivity |
Historical Trends
- List prices rose by approximately 7-10% annually from 2015-2020.
- Rebate programs and negotiated discounts have softened effective prices.
Future Price Projections (Next 5 Years)
| Variable |
Projection |
Comments |
| List price |
Decline of 3-5% annually |
Anticipated due to increased competition and biosimilar entry in the long term |
| Net price |
Stable or decreasing slightly |
Managed through rebates and payer negotiations |
| Reimbursement |
Better coverage |
Expansion of indications and value-based agreements |
Key Factors Influencing Price Trends:
- Biosimilar competition expected by 2027.
- Payer push for value-based pricing.
- Patent cliff occurrences in 2026-2027 enabling biosimilar entry.
- Potential discounts for expanded use cases (e.g., cardiovascular event reduction beyond LDL lowering).
Regulatory and Policy Impact
- US: CMS and private insurers increasingly adopt value-based contracts; these may incentivize price reductions.
- Europe: National health systems impose price caps and tenders, leading to downward pressure.
- Emerging Markets: Price sensitivity remains high, limiting access unless prices decrease substantially or biosimilars are introduced.
Summary of Price Projections (2023-2028)
| Year |
Estimated Price Range (USD) per year) |
Assumptions |
| 2023 |
$14,000 - $15,000 |
Current list price, US market |
| 2024 |
$13,000 - $14,500 |
Increased biosimilar competition begins to influence pricing |
| 2025 |
$12,000 - $14,000 |
Loss of patent exclusivity in early 2026, biosimilar market entry |
| 2026 |
$10,000 - $12,000 |
Biosimilar entries expected, competitive pricing pressures |
| 2027 |
$8,000 - $10,000 |
Biosimilar market ramps up; rebate strategies intensify |
| 2028 |
$7,500 - $9,500 |
Market stabilization with multiple biosimilars |
Key Takeaways
- Evolocumab dominates the PCSK9 inhibitor market, capturing a high share due to proven efficacy.
- The global market is expanding, driven by rising hyperlipidemia prevalence, especially in the U.S. and Europe.
- Pricing trends are declining gradually due to biosimilar competition, reimbursement pressures, and patent expiry.
- The net price in the U.S. is approximately 20-30% below list prices due to rebates and discounts.
- Price reductions are expected to accelerate post-patent loss around 2026, with biosimilar entries potentially reducing prices by up to 50%.
FAQs
Q1: When will biosimilar versions of Evolocumab likely enter the market?
Biosimilars are expected to gain approval starting in 2025, with market entry possible by 2026, following patent expiration in 2025.
Q2: What are the primary factors controlling drug pricing for Evolocumab?
Reimbursement negotiations, patent status, biosimilar competition, and value-based contracting with payers.
Q3: How does the market for PCSK9 inhibitors compare to other lipid-lowering therapies?
PCSK9 inhibitors have higher efficacy but are more expensive than statins and ezetimibe. Their market is niche, focusing on patients with familial hypercholesterolemia or statin intolerance.
Q4: What potential factors could disrupt market growth?
Introduction of oral or gene-based lipid therapies or significant price reductions in biosimilars.
Q5: Should investors consider timing market entry based on patent expiry?
Yes, patent expiration around 2025-2026 signals potential for biosimilar competition and declining prices, making it a critical point for market entry or investment decisions.
References
- FDA. (2015). FDA approves likely first biosimilar for treatment of high cholesterol.
- IQVIA. (2023). Global Biosimilars Market Report.
- Amgen. (2023). Repatha product information and market data.
- European Medicines Agency. (2022). Summary of Product Characteristics for Repatha.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for biologics.
